NCT04067999 - A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

July 19, 2021

Study Completion Date

July 19, 2021

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.

Trial Locations (16)

15006

Novo Nordisk Investigational Site, A Coruña

15401

Novo Nordisk Investigational Site, Ferrol

27700

Novo Nordisk Investigational Site, Ribadeo

31008

Novo Nordisk Investigational Site, Pamplona

33011

Novo Nordisk Investigational Site, Oviedo

35001

Novo Nordisk Investigational Site, Las Palmas de Gran Canaria

36071

Novo Nordisk Investigational Site, Pontevedra

36200

Novo Nordisk Investigational Site, Vigo

37007

Novo Nordisk Investigational Site, Salamanca

47010

Novo Nordisk Investigational Site, Valladolid

48013

Novo Nordisk Investigational Site, Bilbao

48903

Novo Nordisk Investigational Site, Barakaldo

48960

Novo Nordisk Investigational Site, Galdakao

01001

Novo Nordisk Investigational Site, Álava

08007

Novo Nordisk Investigational Site, Barcelona

08036

Novo Nordisk Investigational Site, Barcelona